Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,655   13.81  Index Moved Down -0.83%
FNMFO FNMFO 096770 KDDIF Silver Heavy Metals Chemicals Hotels 
United States GSPC USD ...  |  Screen Global Equities


Processing
Processing. Please wait...

QRxPharma One Year Low

 
 Companies |  Insiders  | Dashboard  
     

One Year Low breakdown for QRxPharma

One Year Low is the lowest price that a given equity instrument has reached in the last 52 weeks. In other words it is the lowest price that investors were willing to pay for the asset over the past 52 weeks of trading. Year Low can be used as a naive indicator of how a given equity may perform over longer term investment horizon.

QRxPharma

One Year Low

=

Lowest Price in the Last 52 Weeks

=
5.21
Some investors believe that One Year Low is a good indicator of how the value of a stock is elastic during the trading year. It offers a good prospective on equity performance compared to trading within industry, sector, category or even the entire stock market. For example, if a stock is at its One Year Low with local stock market index is not at its One Year Low, that stock is said to be under-performing the market. On the other hand if the price of a stock is reached a new One Year Low, an investor may interpret it as a turning point and trade the instrument away or go short.
Compare QRxPharma to competition
Based on recorded statements QRxPharma Pty Ltd has One Year Low of 5.21. This is much higher than that of sector, and significantly higher than that of One Year Low industry, The One Year Low for all stocks is over 1000% lower than the firm.

Filter other Stocks by One Year Low

Select One Year Low Range
Current Range 
Indicate Industry
Click to run this filter
 Run Equity Filter
Filter Other Equities
  

One Year Low Comparison

QRxPharma is currently under evaluation in one year low category among related companies.
Follow QRxPharma One Year Low with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add QRxPharma to your reader
 
    
QRXPY United States OTC
QRxPharma Pty Ltd
Benchmark S&P 500
Traded on OTC Market
    
    

Other QRxPharma Fundamentals

Return On Equity(88.89) %
Return On Asset(51.36) %
Current Valuation225.31 M
Shares Outstanding28.86 M
Price to Book9.76 times
Price to Sales616 times
Revenue422.74 K
EBITDA(22.74 M)
Net Income(21 M)
Cash and Equivalents32.37 M
Cash per Share1.12 times
Current Ratio4.90 times
Book Value Per Share0.92 times
Cash Flow from Operations(14.76 M)
One Year High11.72
One Year Low5.21
Earnings Per Share(0.79) times
Number of Employees14
Market Capitalization257.68 M
Probability Of Bankruptcy43.15 %


 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium